Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?

Assembly Biosciences (ASMB) shares rallied 24% in the last trading session to close at $14.18. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 22.9% gain over the past four weeks.The company has four developmental candidates that are being investigated in early-stage studies for treating chronic infections like herpesvirus, hepatitis B virus and hepatitis delta virus. Several clinical data readouts are expected later in 2025. The growing optimism related to the rapid progress of Assembly Biosciences’ antiviral pipeline might have driven the recent share price rally.This biotech drug developer is expected to post quarterly loss of $2.01 per share in its upcoming report, which represents a year-over-year change of -21.1%. Revenues are expected to be $7.76 million, up 34% from the year-ago quarter.Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.For Assembly Biosciences, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ASMB going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Assembly Biosciences belongs to the Zacks Medical - Generic Drugs industry. Another stock from the same industry, Taysha Gene Therapies, Inc. (TSHA), closed the last trading session 7.1% higher at $2.58. Over the past month, TSHA has returned 91.3%.Taysha Gene Therapies' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.08. Compared to the company's year-ago EPS, this represents a change of +20%. Taysha Gene Therapies currently boasts a Zacks Rank of #3 (Hold).Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Assembly Biosciences, Inc. (ASMB): Free Stock Analysis Report Taysha Gene Therapies, Inc. (TSHA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks